Drug treatment of migraine attacks: A pharmacological view;Medikamentell behandling av migreneanfall: Farmakologiske betraktninger

Tidsskrift for den Norske Laegeforening

Volumn 116, Issue 18, 1996, Pages 2176-2179

  Salvesen, Rolf ^a  

^a Nordland Sentralsykehus ^*  (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIEMETIC AGENT; CHLORPROMAZINE; DIHYDROERGOTAMINE; ERGOTAMINE; METOCLOPRAMIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PROCHLORPERAZINE; SUMATRIPTAN;

ANGINA PECTORIS; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG INFORMATION; HEART INFARCTION; HUMAN; MIGRAINE; PARESTHESIA; PHARMACODYNAMICS; REVIEW; VASOSPASM;

ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ERGOTAMINES; HUMANS; MIGRAINE DISORDERS; SEROTONIN ANTAGONISTS; SUMATRIPTAN;

EID: 0029791512     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Stovner LJ. Diagnostikk og behandling av hodepine. Tidsskr Nor Lægeforen 1995; 115: 1627-31.
2. Tfelt-Hansen P, Olesen J. Effervescent metoclopramide and aspirin versus effervescent aspirin or placebo for migraine attacks: a double-blind study. Cephalalgia 1984; 4: 107-11.
3. Ferreira SH. Prostaglandins, aspirin-like drugs and analgesia. Nature New Biol 1972; 240 200-3.
4. Bennett A. Prostaglandins: their release, biological effects and relationships to pain and inflammation Cephalalgia 1986; 6 (suppl 4) 17-20
5. Williams TJ. Interactions between prostaglandins. leukotrienes and other mediators of inflammation. Br Med Bull 1983; 39: 239-42.
6. Buzzi MG, Sakas DE, Moskowitz MA. Indomethacin and ASA block neurogenic plasma protein extravasation in rat dura mater. Eur J Pharmacol 1989: 65: 251-8.
7. Tek DS, McClennan DS, Olshaker JS, Allen CL, Arthur DC. A prospective, double-blind study of metoklopramide hydrochloride for the control of migraine in the emergency department. Ann Emerg Med 1990; 19: 1083-7.
8. Nestvold K, Kloster R, Partinen M, Sulkava R. Treatment of acute migraine attack: naproxen and placebo compared. Cephalalgia 1985; 5: 115-9.
9. Kloster R, Nestvold K, Vilming ST. A double-blind study of ibuprofen versus placebo in the treatment of acute migraine attacks. Cephalalgia 1992; 12: 169-71.
10. Jones S, Sklar D, Dougherty J, White W. Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache. JAMA 1989; 261: 1174-6.
11. Lane PL, McLellan BA, Baggoley CJ. Comparative efficacy of chlorpromazine and meperidine with dimenhydrinate in migraine headache. Ann Emerg Med 1989; 18: 360-5.
12. Bax WA, Renzenbrink GJ, van Heuven-Nolsen D, Thijssen EJM, Bos E. 5HT-receptors mediating contractions of isolated human coronary artery. Eur J Pharmacol 1993; 239: 203-10.
13. Schmidt R, Fanchamps A. Effect of caffeine on intestinal absorption of ergotamine in man. Eur J Clin Pharmacol 1974; 7: 213-6.
14. Quality Standards Subcommittee of the AAN. Summary statement. Neurology 1995; 45: 585-7.
15. Raskin N. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 1986; 36: 995-7.
16. Sleight AJ, Cervenka A, Peroutka SJ. In vivo effects of sumatriptan (GR14375) on extracellular levels of 5-HT in the guinea pig. Neuropharmacology 1990; 29: 551-3.
17. Humphrey PPA, Feniuk W. Mode of action of the antimigraine drug Sumatriptan. Trends Pharmacol Sci 1991; 12: 444-6.
18. Caekebeke JFV, Ferrari MD, Zwets-loot CP, Jansen J, Saxena PR. The antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks. Neurology 1992; 42: 1522-6.
19. Ferran MD, Haan J, Blokland JAK, Minnee P, Zwinderman KH, Saxena PR. Cerebral blood flow during migraine attacks without aura and effect of sumatriptan. Arch Neurol 1995; 52: 135-9.
20. Ferrari MD, Saxena PR. 5-HT1 receptors in migraine pathophysiology and treatment. Eur J Neurol 1995; 2: 5-21.
21. den Boer MO, Villalon CM, Heiligers JPC, Humphrey PPA, Saxena PR. Role of 5-HTI-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan. Br J Pharmacol 1991; 102: 323-30.
22. Connor HE, Stubbs CM, Feniuk W, Humphrey PPA. Effect of sumatriptan, a selective 5-HTI-like receptor agonist, on pial vessel diameter in anaesthetised cats. J Cereb Blood Flow Metab 1992; 12: 514-9.
23. Buzzi MG, Moskowitz MA. The antimigraine drug sumatriptan specifically blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 1990; 99: 202.
24. Goadsby PJ, Edvinsson L. Sumatriptan reverses the changes in CGRP seen in the headache phase of migraine. Cephalalgia 1991; 11 (suppl 11): 3-4.
25. Zochodne DW, Lam TH. Sumatriptan blocks neurogenic inflammation in the peripheral nerve trunk. Neurology 1994; 44: 161-3.
26. Ferrari MD, Saxena PR. Clinical effects and mechanism of action of sumatriptan in migraine. Clin Neurol Neurosurg 1992; 94 (suppl 1): 73-7.
27. Goadsby PJ, Edvinsson L. Central and peripheral trigeminovascular activation in the cat is inhibited by the novel 5HT1D-agonist 311C90. Headache 1994; 34: 299.
28. Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJN. The clinical pharmacology. pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991; 31: 291-4.
29. Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N Engl J Med 1991; 325: 316-21.
30. Oral Sumatriptan International Multiple-Dose Study Group. Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol 1991; 31: 306-13.
31. Brown EG, Endersby CA, Smith RN, Talbot JCC. The safety and tolerability of sumatriptan: an overview. Eur Neurol 1991; 31: 339-44.
32. Tansey MJB, Pilgrim AJ, Lloyd K. Sumatriptan in the acute treatment of migraine. J Neurol Sci 1993; 114; 109-16.
33. Tfelt-Hansen P. Sumatriptan for the treatment of migraine attacks - a review of controlled clinical trials. Cephalalgia 1993; 13: 238-44.
34. Hillis WS, MacIntyre PD. Sumatriptan and chest pain. Lancet 1993; 341: 1564-5.
35. Plosker GL, McTavish D. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1994; 47: 622-51.
36. MacIntyre PD, Bhargava B, Hogg KJ, Gemmill JD, Hillis WS. Effect of subcutaneous sumatriptan, a selective 5-HT1-agonist, on the systemic, pulmonary and coronary circulation. Circulation 1993; 87: 401-5.
37. Evers S, Husstedt IW, Enbergs A. Coronary angiography in migraine patient after subcutaneous sumatriptan. Lancet 1995; 345: 198.
38. Ottervanger JP, Paalman HJA, Boxma GL, Stricker BHC. Transmural myocardial infarction with sumatriptan. Lancet 1993; 341: 861-2.
39. Boyd IW, Rohan AP. Sumatriptan-induced chest pain. Lancet 1994; 344: 1704-5.
40. Houghton LA, Foster JM, Whorwell PJ, Morris J, Fowler P. Is chest pain after sumatriptan oesophageal in origin? Lancet 1994, 344: 985-6.
41. Bates D, Ashford E, Dawson R, Ensinik FB, Gilhus NE, Olesen J et al. Subcutaneous sumatriptan during the migraine aura. Neurology 1994; 44: 1587-92.